Evaxion A/S
No enriched coverage for $EVAX in the last 7 days.
No SEC Form 4 filings for $EVAX in the last 30 days.
Evaxion A/S (NASDAQ: EVAX) will present three-year phase 2 efficacy data for personalized cancer vaccine EVX-01 at ESMO Congress 2026. The data come from an extension in advanced melanoma, including a third-year EVX-01 stand-alone arm. Prior two-year results reported ORR 75% (12/16) and 92% durable clinical benefit at two years, with no relapses.
Evaxion A/S (NASDAQ: EVAX) reported new preclinical poster data for its cytomegalovirus vaccine program EVX-V1 at IHW 2026 in Montreal. The company said AI-discovered T-cell epitopes improved control of acute infection, latency and reactivation in CMV-infected mice, complementing prior B-cell antigen results. EVX-V1 combines novel antigens with an AI-optimized gB antigen.
Evaxion A/S (NASDAQ: EVAX) will present new preclinical data for its cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop 2026 in Montreal on July 12, 2026. EVX-V1 combines AI-discovered antigens with AI-optimized gB. The data will support final antigen selection as the program advances.
Recent EVAX coverage spans financial news and technology.
Conference-bound follow-on clinical data could reinforce EVX-01 efficacy durability and broaden the commercial narrative beyond combination therapy.
Preclinical efficacy reinforcement for EVX-V1 could modestly improve perceived probability of clinical success, but it does not change near-term milestones in the text.
Conference poster signals incremental progress in EVX-V1 preclinical work, but provides no new quantitative results in the article.
Preclinical validation for EVX-04 (expression/secretion + immune activation + cell-killing) supports the company’s path toward regulatory filing and eventual clinical testing.
Evaxion Biotech's new ADS offering indicates a capital raise that could support future growth initiatives. The company's current 'Buy' rating and $16.00 price target suggest analyst confidence, but persistent net losses and a somewhat bearish sentiment imply caution.
alphai scores every news story that mentions EVAX with an AI model for sentiment and relevance, and aggregates insider trades from Evaxion A/S's SEC EDGAR Form 4 filings. Figures refresh continuously.
Evaxion A/S (NASDAQ: EVAX) will present three-year phase 2 efficacy data for personalized cancer vaccine EVX-01 at ESMO Congress 2026. The data come from an extension in advanced melanoma, including a third-year EVX-01 stand-alone arm. Prior two-year results reported ORR 75% (12/16) and 92% durable clinical benefit at two years, with no relapses.
2 min readEvaxion A/S (NASDAQ: EVAX) reported new preclinical poster data for its cytomegalovirus vaccine program EVX-V1 at IHW 2026 in Montreal. The company said AI-discovered T-cell epitopes improved control of acute infection, latency and reactivation in CMV-infected mice, complementing prior B-cell antigen results. EVX-V1 combines novel antigens with an AI-optimized gB antigen.
2 min readEvaxion A/S (NASDAQ: EVAX) will present new preclinical data for its cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop 2026 in Montreal on July 12, 2026. EVX-V1 combines AI-discovered antigens with AI-optimized gB. The data will support final antigen selection as the program advances.
3 min readEvaxion A/S (NASDAQ: EVAX) reported new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia. The company said EVX-04 is fully expressed and secreted in human cells and that its ERV tumor antigens trigger specific immune responses and targeted cell-killing in mice and human in vitro models across different immune profiles. Data will be presented in a June 13, 2026 EHA poster in Stockholm.
4 min readEvaxion Biotech A/S has filed a prospectus supplement with the SEC for the offer and sale of American Depositary Shares (ADSs) worth up to $45.5 million. This financial move, part of an existing sales agreement with JonesTrading Institutional Services LLC, aims to strengthen the company's capital and market standing. The company currently holds a "Buy" rating from analysts with an average price target of $16.00, though its valuation is noted as unattractive due to persistent net losses.
4 min readCOPENHAGEN, Denmark, November 7, 2025 - Evaxion A/S ( NASDAQ: EVAX ) ( "Evaxion" ) , a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new data exploring immune responses following treatment with AI-designed personalized cancer vaccine EVX-01.
3 min readCorrecting press release issued under same heading: Date in body text corrected to "November 6, 2025" as in headline.
2 min readCOPENHAGEN, Denmark, October 17, 2025 - Evaxion A/S ( NASDAQ: EVAX ) ( "Evaxion" ) , a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new two-year unprecedented clinical efficacy data of its personalized cancer vaccine EVX-01 in patients with ...
3 min readPresentation will cover two-year clinical efficacy, immunogenicity and safety data Data will be presented at an oral session on October 17, 2025, followed by a webinar on October 22, 2025, providing further insights into the clinical findings
4 min readCOPENHAGEN, Denmark, October 13, 2025 - Evaxion A/S ( NASDAQ: EVAX ) ( "Evaxion" ) , a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present a wide range of data from its phase 2 trial with lead compound EVX-01 at the European Society for Medical ...
4 min read
